Literature DB >> 26828584

Indications and contraindications for infusing specific amino acids (leucine, glutamine, arginine, citrulline, and taurine) in critical illness.

Antonin Ginguay1, Jean-Pascal De Bandt, Luc Cynober.   

Abstract

PURPOSE OF REVIEW: The review assesses the utility of supplementing parenteral or enteral nutrition of ICU patients with each of five specific amino acids that display pharmacological properties. Specifying indications implies also stating contraindications.Combined supplementation of amino acids with ω3-fatty acids and/or trace elements (immune-enhancing diets) will not be considered in this review because these mixtures do not allow the role of amino acids in the effect (positive or negative) of the mixture to be isolated, and so cannot show whether or not supplementation of a given amino acid is indicated. RECENT
FINDINGS: After decades of unbridled use of glutamine (GLN) supplementation in critically ill patients, recent large trials have brought a note of caution, indicating for example that GLN should not be used in patients with multiple organ failure. Yet these large trials do not change the conclusions of recent meta-analyses. Arginine (ARG), as a single dietary supplement, is probably not harmful in critical illness, in particular in a situation of ARG deficiency syndrome with low nitric oxide production. Citrulline supplementation strongly improves microcirculation in animal models with gut injury, but clinical studies are lacking. Taurine has a potent protective effect against ischemic reperfusion injury.
SUMMARY: Amino acid-based pharmaconutrition has displayed familiar 'big project' stages: enthusiasm (citrulline and taurine), doubt (GLN), hunt for the guilty (ARG), and backpedalling (leucine). Progress in this field is very slow, and sometimes gives way to retreat, as demonstrated by recent large trials on GLN supplementation.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26828584     DOI: 10.1097/MCO.0000000000000255

Source DB:  PubMed          Journal:  Curr Opin Clin Nutr Metab Care        ISSN: 1363-1950            Impact factor:   4.294


  6 in total

1.  Evaluation of the Neuroprotective Effect of Magnesium-Bis-(2-Aminoethanesulfonic)-Butanedioate in Simulated Ischemic Stroke in Rats.

Authors:  N I Nesterova; V V Pokrovskii; E A Patrakhanov; I V Pirozhkov; T G Pokrovskaya; N B Levit; I M I; S N M Kizi; A V Nesterov; V I Shutov; Y Yuri A Hoshchenko
Journal:  Arch Razi Inst       Date:  2021-10-01

2.  Argininemia and plasma arginine bioavailability - predictive factors of mortality in the severe trauma patients?

Authors:  Beatriz P Costa; Paulo Martins; Carla Veríssimo; Marta Simões; Marisa Tomé; Manuela Grazina; Jorge Pimentel; Francisco Castro-Sousa
Journal:  Nutr Metab (Lond)       Date:  2016-08-31       Impact factor: 4.169

3.  Protective Roles and Mechanisms of Taurine on Myocardial Hypoxia/Reoxygenation-Induced Apoptosis.

Authors:  Xiaohong Yang; Jingjing Fu; Huifang Wan; Zhuoqi Liu; Lehan Yu; Bo Yu; Fusheng Wan
Journal:  Acta Cardiol Sin       Date:  2019-07       Impact factor: 2.672

4.  Taurine ameliorates thioacetamide induced liver fibrosis in rats via modulation of toll like receptor 4/nuclear factor kappa B signaling pathway.

Authors:  Nancy S Younis; Amal M H Ghanim; Mohammad A Elmorsy; Heba A Metwaly
Journal:  Sci Rep       Date:  2021-06-10       Impact factor: 4.379

Review 5.  Parenteral Nutrition: Amino Acids.

Authors:  Leonard John Hoffer
Journal:  Nutrients       Date:  2017-03-10       Impact factor: 5.717

Review 6.  Effects and Mechanisms of Taurine as a Therapeutic Agent.

Authors:  Stephen Schaffer; Ha Won Kim
Journal:  Biomol Ther (Seoul)       Date:  2018-05-01       Impact factor: 4.634

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.